



June 12, 2026

Boehringer Ingelheim
Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877

Dear PDAB Board Members and Staff,

At Boehringer Ingelheim, we recognize the challenges within the U.S. healthcare system—particularly the burden patients face when confronted with high out-of-pocket costs at the pharmacy counter. We share the Board’s objectives of improving affordability and ensuring sustainable access to medicines. Jardiance® was reviewed as recently as 2025 and determined not to present an affordability challenge for either healthcare systems or patients’ out-of-pocket costs¹. Given this prior assessment and its continued demonstrated value, **we respectfully ask the Board to once again deem Jardiance® affordable.**

We are confident in the value that Jardiance® brings to patients and the healthcare system and believe the value must be considered when evaluating cost to state. Jardiance® is the number one prescribed SGLT2 inhibitor with 59 million prescriptions in the US. To date, we estimate that the use of Jardiance has extended the lives of treated patients by more than 461,000 patient-life years². Boehringer is committed to affordability for our patients and approximately 88% of Jardiance® patients pay no more than \$50 for their prescriptions due to our multiple assistance programs, with the average Oregon patient paying no more than \$30³.

It is important to recognize that manufacturers represent only one part of a much larger drug pricing and reimbursement system. Patients within the US healthcare system face access and affordability barriers due to the business practices of pharmacy benefit managers (PBMS). We urge the Board to take a holistic view of cost drivers by examining the role of PBMs and pursuing solutions that improve transparency and accountability across the supply chain.

Boehringer supports the Board’s mission to improve affordability for Oregon patients and maintains Jardiance meets this standard and should not be deemed to pose an affordability challenge. We remain committed to working collaboratively on solutions that sustain patient access while supporting continued medical innovation.

Regards,

Signed by:

F5069C0EFC26442...

Candie Finnegan
Executive Director, State Government Affairs

¹ Final Prescription Drug List for Oregon PDAB 2025 review. <https://dfr.oregon.gov/pdab/Documents/Final-prescription-medication-list-20260121.pdf>

² Jardiance Selection by CMS for Drug Price Negotiation. 2023. <https://www.boehringer-ingelheim.com/us/human-health/statement-boehringer-ingelheim-selection-jardiance-empagliflozin-centers-medicare-and-medicaid>

³ IQVIA LAAD and all paid claims in 2025